A federal appeals court won’t upend Morrisville-based Liquidia’s loss in a patent dispute with United Therapeutics that threatens to stall the U.S. launch of Liquidia’s Yutrepia treatment for pulmonary arterial hypertension.
Read More
Triangle-based Liquidia has struck an exclusive licensing deal for North America with Taiwan-based Pharmosa Biophram around a new drug to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It’s now in clinical trial.
Read More
Biopharma firm Liquidia has struck a deal for $100 million in capital that it says “extends [its] cash runway” and provides funds for launch of its lead product that targets pulmonary arterial hypertension if and when patent litigation over the treatment is resolved
Read More
It’s been a busy week for North Carolina public companies in tech and life science reporting financial results. Here’s a roundup.
Read More
Triangle biopharma Liquidia has doubled the size of its credit facility to $40 million after naming a new chief executive officer. Here are the details.
Read More
Triangle drug firm Liquidia’s legal battle with United Therapeutics over patent issues and a new drug to treat pulmonary arterial hypertension is still headed for a court trial in March, but the company’s CEO is encouraged by a “partial judgment” in ongoing legal proceedings.
Read More
One month after a favorable ruling in a patent dispute, Morrisville-based Liquidia has gained tentative approval from the U.S. Food and Drug Administration for Yutrepia, its inhalation powder for treating pulmonary arterial hypertension. Here are the details.
Read More
RESEARCH TRIANGLE PARK – Life science firm Liquidia, fresh off an acquisition and continuing to push development of its lead drug candidate, now has a new chief financial officer. Michael Kaesta, a veteran executive with previous experience at Sanofi among other drug firms, replaces interime CFO Steve Bariahtaris. The...
Read More
Shares in Liqudia (Nasdaq: LQDA) declined more than 6% early Wednesday when the life science firm says the FDA did not approve its new drug application for a treatment of pulmonary arterial hypertension.
Read More
